Showing results (111-120 of 142) with videos related to

Sort By:
Pageof 15
Frontiers in Oncology|January 31, 2019
Molecular Measurable Residual Disease Testing of Blood During AML Cytotoxic Therapy for Early Prediction of Clinical ResponseHong Yuen Wong, Anthony D Sung, Katherine E Lindblad, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2018
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid LeukemiaJeffrey E Lancet, Geoffrey L Uy, Jorge E Cortes, et al.
Blood Advances|January 28, 2020
Highly multiplexed proteomic assessment of human bone marrow in acute myeloid leukemiaHaydar Çelik, Katherine E Lindblad, Bogdan Popescu, et al.
European Journal of Haematology|December 27, 2024
Tumor Lysis Syndrome in Acute Myeloid Leukemia Patients Treated With a Venetoclax Based RegimenMargaret Rowe, Daria Babushok, Martin Carroll, et al.
The New England Journal of Medicine|January 21, 2026
Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast CancerSara M Tolaney, Evandro de Azambuja, Kevin Kalinsky, et al.
Blood Advances|February 24, 2026
Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapyAndrew H Wei, Panayiotis Panayiotidis, Pau Montesinos, et al.
JACC. Advances|June 18, 2026
Cardiovascular Events in Patients With Acute Myeloid Leukemia Treated With Venetoclax: A Multicenter Cohort StudySabin Filimon, Azin Ghamari, Azin Vakilpour, et al.
Blood Advances|January 31, 2025
Evolving racial/ethnic disparities in AML survival in the novel therapy eraXin Wang, Phyllis A Gimotty, Andrew H Matthews, et al.
Blood Advances|November 21, 2025
Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapyAndrew H Wei, Panayiotis Panayiotidis, Pau Montesinos, et al.
Cancer Research Communications|June 25, 2025
A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 YearsEric D Eisenmann, Ronan Swords, Ying Huang, et al.
Pageof 15